351 related articles for article (PubMed ID: 24832158)
1. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.
Lasota J; Kowalik A; Wasag B; Wang ZF; Felisiak-Golabek A; Coates T; Kopczynski J; Gozdz S; Miettinen M
Am J Surg Pathol; 2014 Sep; 38(9):1235-41. PubMed ID: 24832158
[TBL] [Abstract][Full Text] [Related]
2. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
Adackapara CA; Sholl LM; Barletta JA; Hornick JL
Histopathology; 2013 Aug; 63(2):187-93. PubMed ID: 23763264
[TBL] [Abstract][Full Text] [Related]
4. Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E.
Mesteri I; Bayer G; Meyer J; Capper D; Schoppmann SF; von Deimling A; Birner P
Mod Pathol; 2014 Jan; 27(1):135-44. PubMed ID: 23887306
[TBL] [Abstract][Full Text] [Related]
5. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.
Dvorak K; Higgins A; Palting J; Cohen M; Brunhoeber P
Pathol Oncol Res; 2019 Jan; 25(1):349-359. PubMed ID: 29127628
[TBL] [Abstract][Full Text] [Related]
7. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
Vallée A; Denis-Musquer M; Herbreteau G; Théoleyre S; Bossard C; Denis MG
PLoS One; 2019; 14(8):e0221123. PubMed ID: 31415669
[TBL] [Abstract][Full Text] [Related]
9. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
10. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
Huang WK; Kuo TT; Wu CE; Cheng HY; Hsieh CH; Hsieh JJ; Shen YC; Hou MM; Hsu T; Chang JW
Asia Pac J Clin Oncol; 2016 Dec; 12(4):403-408. PubMed ID: 27488807
[TBL] [Abstract][Full Text] [Related]
11. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.
Rössle M; Sigg M; Rüschoff JH; Wild PJ; Moch H; Weber A; Rechsteiner MP
Virchows Arch; 2013 Nov; 463(5):623-31. PubMed ID: 24085553
[TBL] [Abstract][Full Text] [Related]
12. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB
J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234
[TBL] [Abstract][Full Text] [Related]
13. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.
Gonsalves WI; Mahoney MR; Sargent DJ; Nelson GD; Alberts SR; Sinicrope FA; Goldberg RM; Limburg PJ; Thibodeau SN; Grothey A; Hubbard JM; Chan E; Nair S; Berenberg JL; McWilliams RR;
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24925349
[TBL] [Abstract][Full Text] [Related]
14. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
15. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity.
Bledsoe JR; Kamionek M; Mino-Kenudson M
Am J Surg Pathol; 2014 Oct; 38(10):1418-28. PubMed ID: 24921639
[TBL] [Abstract][Full Text] [Related]
17. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
Yaman B; Kandiloğlu G; Akalin T
Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
[TBL] [Abstract][Full Text] [Related]
18. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.
Estrella JS; Tetzlaff MT; Bassett RL; Patel KP; Williams MD; Curry JL; Rashid A; Hamilton SR; Broaddus RR
Mol Cancer Ther; 2015 Dec; 14(12):2887-95. PubMed ID: 26438153
[TBL] [Abstract][Full Text] [Related]
19. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
20. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]